Pre- and postoperative treatment of basid disease with iodine. Niсоlaysen (Deut. m. Woch., 1926, no. 16)

1926 ◽  
Vol 22 (12) ◽  
pp. 1390-1390
Author(s):  
L. Ratner
Keyword(s):  
Postoperative Treatment ◽  
Graves Disease ◽  
Preoperative Treatment ◽  
Vascular Ligation ◽  
Iodine Treatment

The author is disappointed in the usual methods of preoperative treatment of Graves' disease. He rejects both resting position, preoperative vascular ligation, and radiotherapy, advising preoperative and postoperative iodine treatment instead.

scholarly journals Preoperative denosumab treatment with curettage may be a risk factor for recurrence of giant cell tumor of bone

2020 ◽  
Vol 28 (2) ◽  
pp. 230949902092978
Author(s):  
Kei Sano ◽  
Yoshiyuki Suehara ◽  
Taketo Okubo ◽  
Keita Sasa ◽  
Taisei Kurihara ◽  
...  
Keyword(s):  
Giant Cell Tumor ◽  
Giant Cell ◽  
Cell Tumor ◽  
Clinicopathological Features ◽  
Postoperative Treatment ◽  
Preoperative Treatment ◽  
Effective Treatment Option ◽  
Surgical Treatments ◽  
The Relationship ◽  
Denosumab Treatment

Purpose: Giant cell tumor of bone (GCTB) is a local aggressive bone tumor, histologically classified as intermediate malignancy. Recently, the RANKL inhibitor, denosumab, was developed as a novel and effective treatment option for GCTB. Since the risk of preoperative use of denosumab with curettage had been previously reported, this study aimed to investigate the relationship between recurrences and clinicopathological features associated with adjuvant denosumab treatment in GCTB. Methods: A total of 87 GCTB cases were treated at our institution. We reviewed 66 patients with conventional-type GCTB occurring in the extremities and analyzed 78 surgical treatments, including curettages and resections, with clinicopathological features and denosumab treatment. Results: GCTB lesions, including 66 primary and 12 recurring, underwent surgical treatment like curettage and resection. Recurrence-free survivals in 78 GCTB surgeries were 78.7% in 3 years and 71.9% in 5 years. In the resected cases of GCTBs, there was no recurrence either with or without denosumab. In curettage cases, 3-year recurrence-free survivals were 0.0% ( n = 3) in preoperative treatment of denosumab, 66.7% ( n = 6) in postoperative treatment, and 76.6% ( n = 43) in no treatment. Interestingly, three preoperative treatment cases demonstrated low MIB-1 index despite 100% recurrence. The other clinicopathological factors did not contribute much to the risk of recurrence in curettage cases. Conclusion: Our findings revealed the use of denosumab in GCTB, prior to curettage, to possibly increase the risk of local recurrence. Together with previous reports, our finding might provide information for beneficial treatment of GCTB.

scholarly journals A phase II study of liposomal irinotecan with 5-fluorouracil, leucovorin and oxaliplatin in patients with resectable pancreatic cancer: the nITRO trial

2020 ◽  
Vol 12 ◽  
pp. 175883592094796
Author(s):  
Francesca Simionato ◽  
Camilla Zecchetto ◽  
Valeria Merz ◽  
Alessandro Cavaliere ◽  
Simona Casalino ◽  
...  
Keyword(s):  
Pancreatic Cancer ◽  
Phase Ii ◽  
Trial Registration ◽  
Postoperative Treatment ◽  
R0 Resection ◽  
Preoperative Treatment ◽  
Resectable Pancreatic Cancer ◽  
Perioperative Treatment ◽  
Metastatic Relapse ◽  
Liposomal Irinotecan

Background: Up-front surgery followed by postoperative chemotherapy remains the standard paradigm for the treatment of patients with resectable pancreatic cancer. However, the risk for positive surgical margins, the poor recovery after surgery that often impairs postoperative treatment, and the common metastatic relapse limit the overall clinical outcomes achieved with this strategy. Polychemotherapeutic combinations are valid options for postoperative treatment in patients with good performance status. liposomal irinotecan (Nal-IRI) is a novel nanoliposome formulation of irinotecan that accumulates in tumor-associated macrophages improving the therapeutic index of irinotecan and has been approved for the treatment of patients with metastatic pancreatic cancer after progression under gemcitabine-based therapy. Thus, it remains of the outmost urgency to investigate introduction of the most novel agents, such as nal-IRI, in perioperative approaches aimed at increasing the long-term effectiveness of surgery. Methods: The nITRO trial is a phase II, single-arm, open-label study to assess the safety and the activity of nal-IRI with fluorouracil/leucovorin (5-FU/LV) and oxaliplatin in the perioperative treatment of patients with resectable pancreatic cancer. The primary tumor must be resectable with no involvement of the major arteries and no involvement or <180° interface between tumor and vessel wall of the major veins. A total of 72 patients will be enrolled to receive a perioperative treatment of three cycles before and three cycles after surgical resection with nal-IRI 50 mg/m2, oxaliplatin 60 mg/m2, leucovorin 200 mg/m2, and 5-fluorouracil 2400 mg/m2, days 1 and 15 of a 28-day cycle. The primary objective is to improve from 40% to 55% the proportion of patients achieving R0 resection after preoperative treatment. Discussion: The nITRO trial will contribute to strengthen the clinical evidence supporting perioperative strategies in resectable pancreatic cancer patients. Moreover, this study represents a unique opportunity for translational analyses aimed to identify novel immune-related prognostic and predictive factors in this setting. Trial registration Clinicaltrial.gov : NCT03528785. Trial registration data: 1 January 2018 Protocol number: CRC 2017_01 EudraCT Number: 2017-000345-46

scholarly journals Effect of Lugol Solution on Thyroid Gland Blood Flow and Microvessel Density in the Patients with Graves’ Disease

2007 ◽  
Vol 92 (6) ◽  
pp. 2182-2189 ◽  
Author(s):  
Yeşim Erbil ◽  
Yasemin Ozluk ◽  
Murat Giriş ◽  
Artur Salmaslıoglu ◽  
Halim Issever ◽  
...  
Keyword(s):  
Clinical Trial ◽  
Blood Flow ◽  
Thyroid Gland ◽  
Blood Loss ◽  
Microvessel Density ◽  
Solution Treatment ◽  
Graves Disease ◽  
Preoperative Treatment ◽  
Cd 34 ◽  
Lugol Solution

Abstract Context: Although some endocrine surgeons administer Lugol solution to decrease thyroid gland vascularity, there is still not an agreement on its effectiveness. Objective: The aims of this clinical trial are to evaluate thyroid blood flow and microvessel density in patients with Graves’ disease who received Lugol solution treatment preoperatively. Design: This was a prospective clinical trial. Setting: This clinical trial took place at a tertiary referral center. Method: Thirty-six patients were randomly assigned to receive either preoperative treatment with Lugol solution (group 1, n = 17) or no preoperative treatment with Lugol solution (group 2, n = 19). Main Outcome Measures: Blood flow through the thyroid arteries of patients with Graves’ disease was measured by color flow Doppler ultrasonography. The microvessel density (MVD) was assessed by immunohistochemical and Western blot analysis of the level of expression of CD-34 in thyroid tissue. The weight and blood loss of the thyroid gland were measured in all patients. Results: The mean blood flow, MVD, CD-34 expression, and blood loss in group 1 patients were significantly lower than those in group 2 patients. There was a negative correlation between Lugol solution treatment and blood flow (rs = −0.629; P = 0.0001), blood loss (rs = −0.621; P = 0.0001), MVD (rs = −0.865; P = 0.0001), and CD-34 expression (rs = −0.865; P = 0.0001). According to logistic regression analysis, Lugol solution treatment resulted in a 9.33-fold decreased rate of intraoperative blood loss. Conclusion: Preoperative Lugol solution treatment decreased the rate of blood flow, thyroid vascularity, and intraoperative blood loss during thyroidectomy.

scholarly journals Preoperative Treatment with Lugol Solution for Graves' Disease

2019 ◽  
Vol 19 (4) ◽  
pp. 157
Author(s):  
Özer Makay ◽  
Hui Sun ◽  
Ettore Caruso ◽  
Antonella Pino ◽  
Alessandro Pontin ◽  
...  
Keyword(s):  
Graves Disease ◽  
Preoperative Treatment ◽  
Lugol Solution
Sign in / Sign up

Export Citation Format

Share Document